In Wednesday’s pre-market trading, shares of Novo Nordisk A/S (NYSE:NVO) are witnessing a fall after the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) approved a new indication for Novo Nordisk’s semaglutide, Wegovy, to reduce the risk of heart complications or strokes in overweight and obese adults, What Happened: At the time of writing, Novo Nordisk was trading 1.25% lower at $131.61 in the pre-market after closing at $133.28 on Tuesday, according to Benzinga Pro. The weak pre-market performance can also be linked to increased competition in the weight loss drugs market. …
